tiprankstipranks
Trending News
More News >
Keros Therapeutics (KROS)
NASDAQ:KROS
US Market

Keros Therapeutics (KROS) Ratios

Compare
331 Followers

Keros Therapeutics Ratios

KROS's free cash flow for Q4 2024 was $1.00. For the 2024 fiscal year, KROS's free cash flow was decreased by $ and operating cash flow was $-9.69. See a summary of the company’s cash flow.
Ratios
TTM
Dec 24Dec 23Dec 22Dec 21
Liquidity Ratios
Current Ratio
21.45 14.25 17.27 21.23 37.27
Quick Ratio
21.45 14.25 17.32 20.97 37.06
Cash Ratio
20.40 13.59 16.86 19.42 37.01
Solvency Ratio
-4.20 -4.02 -3.51 -4.79 -5.80
Operating Cash Flow Ratio
-5.86 -5.11 -4.23 -5.25 -5.14
Short-Term Operating Cash Flow Coverage
-81.33 0.00 -153.98 -72.10 -87.22
Net Current Asset Value
$ ―$ ―$ ―$ ―$ ―
Leverage Ratios
Debt-to-Assets Ratio
0.03 0.04 0.04 <0.01 <0.01
Debt-to-Equity Ratio
0.03 0.04 0.05 <0.01 <0.01
Debt-to-Capital Ratio
0.03 0.04 0.05 <0.01 <0.01
Long-Term Debt-to-Capital Ratio
0.03 0.00 0.04 <0.01 <0.01
Financial Leverage Ratio
1.08 1.11 1.11 1.05 1.03
Debt Service Coverage Ratio
-94.10 0.00 -226.02 -67.42 -104.31
Interest Coverage Ratio
0.00 0.00 -114.79K -14.09K -7.78K
Debt to Market Cap
0.03 0.00 0.01 <0.01 <0.01
Interest Debt Per Share
0.50 0.49 0.53 0.05 0.06
Net Debt to EBITDA
Profitability Margins
Gross Profit Margin
100.00%-439.74%0.00%95.53%0.00%
EBIT Margin
-5269.10%-101319.21%0.00%-282.23%0.00%
EBITDA Margin
-5234.48%-100779.47%0.00%-280.46%0.00%
Operating Profit Margin
-5938.96%-112543.71%0.00%-280.46%0.00%
Pretax Profit Margin
-5269.10%-101319.21%0.00%-282.25%0.00%
Net Profit Margin
-5277.55%-101319.21%0.00%-292.26%0.00%
Continuous Operations Profit Margin
-5277.55%-101319.21%0.00%-292.26%0.00%
Net Income Per EBT
100.16%100.00%100.00%103.54%99.62%
EBT Per EBIT
88.72%90.03%91.19%100.64%97.59%
Return on Assets (ROA)
Return on Equity (ROE)
Return on Capital Employed (ROCE)
Return on Invested Capital (ROIC)
Return on Tangible Assets
Earnings Yield
Efficiency Ratios
Receivables Turnover
1.29 0.14 0.00 1.12 0.00
Payables Turnover
0.00 0.15 0.48 0.25 0.28
Inventory Turnover
0.00 0.00 -1.92 0.29 0.41
Fixed Asset Turnover
0.15 <0.01 0.00 8.37 0.00
Asset Turnover
<0.01 <0.01 0.00 0.08 0.00
Working Capital Turnover Ratio
Cash Conversion Cycle
Days of Sales Outstanding
Days of Inventory Outstanding
Days of Payables Outstanding
Operating Cycle
Cash Flow Ratios
Operating Cash Flow Per Share
-4.30 -4.23 -2.78 -2.66 -2.38
Free Cash Flow Per Share
-4.35 -4.31 -2.82 -2.71 -2.40
CapEx Per Share
0.05 0.08 0.05 0.04 0.02
Free Cash Flow to Operating Cash Flow
1.01 1.02 1.02 1.02 1.01
Dividend Paid and CapEx Coverage Ratio
-83.31 -50.53 -56.46 -60.69 -125.49
Capital Expenditure Coverage Ratio
-83.31 -50.53 -56.46 -60.69 -125.49
Operating Cash Flow Coverage Ratio
Operating Cash Flow to Sales Ratio
Free Cash Flow Yield
Valuation Ratios
Price-to-Earnings (P/E) Ratio
-3.16 -7.65 -11.58 -23.24 -24.11
Price-to-Sales (P/S) Ratio
166.94 7.75K 0.00 67.92 0.00
Price-to-Book (P/B) Ratio
1.04 3.52 4.37 5.61 4.18
Price-to-Free Cash Flow (P/FCF) Ratio
-3.64 -9.22 -17.00 -21.61 -29.41
Price-to-Operating Cash Flow Ratio
-3.68 -9.40 -17.30 -21.97 -29.65
Price-to-Earnings Growth (PEG) Ratio
0.82 -0.30 -0.18 1.66 -0.22
Price-to-Fair Value
1.04 3.52 4.37 5.61 4.18
Enterprise Value Multiple
-0.28 -5.61 -9.18 -20.16 -18.45
EV to EBITDA
EV to Sales
EV to Free Cash Flow
EV to Operating Cash Flow
Tangible Book Value Per Share
15.27 11.28 10.99 10.42 16.88
Shareholders’ Equity Per Share
15.27 11.28 10.99 10.42 16.88
Tax and Other Ratios
Effective Tax Rate
>-0.01 0.00 >-0.01 -0.04 <0.01
Revenue Per Share
0.09 <0.01 0.00 0.86 0.00
Net Income Per Share
-5.00 -5.20 -4.15 -2.52 -2.93
Tax Burden
Interest Burden
Research & Development to Revenue
SG&A to Revenue
Stock-Based Compensation to Revenue
Income Quality
Currency in USD
What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis